- Have recently recurred or their cancer has progressed and they have had or will have another surgery or biopsy to remove tumor tissue. If a biopsy is not planned, part of the tumor blueprint can be performed on a sample from a previous surgery.
- Have been recently diagnosed with advanced (stage III or IV) cancer characterized as clear cell or mucinous histology or carcinosarcoma.
- Have been recently diagnosed with advanced (stage III or IV) cancer characterized as high grade serous and have a negative result for germline BRCA testing of their blood. Presence of a BRCA gene mutation in the tumor could suggest PARP inhibitor maintenance therapy. Information from this testing can also be helpful to women who are considering entering a clinical trial for first-line or maintenance treatment.
Clearity will need a small piece of tumor tissue or cells obtained from fluid in the lungs or the abdomen to do this testing. We recommend that women who have a biopsy planned or fluid to be drained contact us before the procedure to ensure the sample is properly collected and prepared. Our team will work with the appropriate clinicians to arrange testing of the sample.